You are here: Industry Insights > Regeneron

News List

Sanofi, Regeneron splitting up on Praluent, Kevzara fiercepharma
December 11, 2019
After more than a decade of working together, Sanofi and Regeneron's drug partnership finally turned a profit recently on the back of strong sales of blockbuster Dupixent.
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 americanpharmaceuticalreview
September 03, 2019
Regeneron Pharmaceuticals and Sanofi announced the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen's asserted patent claims for antibodies targeting PCSK9 ...
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha fiercepharma
September 02, 2019
Sanofi and Regeneron have been battling with PCSK9 rival Amgen over patents on their cholesterol drugs for years, with Amgen at one point blocking sales of the partners’ Praluent. Now, Sanofi and Regeneron have persuaded a judge that certain claims of two
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol drugs
August 16, 2019
Regeneron Pharmaceuticals, Inc. today announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody...
Regeneron's Eylea snags prefilled syringe approval as Novartis rival looms fiercepharma
August 15, 2019
Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?
Regeneron plots $800M New York production push—along with 1,500 new jobs fiercepharma
August 15, 2019
Regeneron is humming along on the strength of flagship eye med Eylea and fast-launching immunology drug Dupixent. Now, the drugmaker is investing $800 million in its New York operations to keep up with the growth.
Regeneron Announces Positive Topline Results from Evinacumab Trial americanpharmaceuticalreview
August 15, 2019
Regeneron Pharmaceuticals announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia (HoFH).
Regeneron's Eylea snags pre-filled syringe approval as Novartis rival looms fiercepharma
August 14, 2019
Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?
Sanofi and Regeneron get EU approval for Dupixent expresspharma
August 07, 2019
European Commission has extended marketing authorisation for Dupixent European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis
Regeneron's Eylea pads its armor with diabetic retinopathy approval fiercepharma
May 15, 2019
With a major challenger on the fast track to approval in Novartis’ brolucizumab, Regeneron’s Eylea has been on the hunt for a new indication to boost its best-in-class sales.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page